US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rapport Therapeutics, Inc.

12.04

+0.24002.03%

Post-market: 12.040.00000.00%13:04 EDT

Volume:60.88K

Turnover:742.28K

Market Cap:439.43M

PE:-4.39

High:12.57

Open:12.06

Low:11.95

Close:11.80

Loading ...

Overview Company News Filings

Rapport Therapeutics files to sell 470,589 shares of common stock for holders

Rapport Therapeutics Files Prospectus Relates to Proposed Resale From Time to Time by Selling Stockholder of up to 470,589 Shares

THOMSON REUTERS

Rapport Therapeutics Inc: Sales Agreement Prospectus Covers Offer of Shares of Common Stock of up to $150 Mln From Time to Time

THOMSON REUTERS

Rapport Therapeutics Inc Files for Mixed Shelf of up to $400 Mln – SEC Filing

THOMSON REUTERS

Rapport Therapeutics Inc. Held Annual Stockholders Meeting

Chief Scientific Officer David Bredt Reports Disposal of Common Shares of Rapport Therapeutics Inc

Analysts Offer Insights on NA Companies: Tempus AI, Inc. Class A (TEM) and Rapport Therapeutics, Inc. (RAPP)

Stifel Nicolaus Keeps Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)

Rapport Therapeutics Completes Enrollment for Phase 2a Trial

Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates

THOMSON REUTERS

Rapport Therapeutics Inc. Set to Participate in Jefferies Global Healthcare Conference

Rapport Therapeutics Inc. to Host Inaugural Investor and Analyst Day in New York City

Chief Scientific Officer David Bredt Reports Disposal of Common Shares of Rapport Therapeutics Inc

Rapport Therapeutics Reports Q1 2025 Financial Results

Optimistic Buy Rating for Rapport Therapeutics Driven by Promising RAP-219 Developments

Promising Clinical Developments and Strategic Initiatives Drive Buy Rating for Rapport Therapeutics, Inc.

Rapport Therapeutics Inc - Rap-219 Phase 2a Trial Results Expected Q3 2025 - SEC Filing

THOMSON REUTERS

Rapport Therapeutics Q1 EPS $(0.68) Beats $(0.76) Estimate

-Charles River agrees with Elliott to add new directors, review business

Stifel Nicolaus Sticks to Its Buy Rating for Rapport Therapeutics, Inc. (RAPP)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/RAPP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RAPP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAPP\",,,,,undefined,":{"symbol":"RAPP","market":"US","secType":"STK","nameCN":"Rapport Therapeutics, Inc.","latestPrice":12.04,"timestamp":1751562000000,"preClose":11.8,"halted":0,"volume":60881,"hourTrading":{"tag":"盘后","latestPrice":12.04,"preClose":12.04,"latestTime":"13:04 EDT","volume":4652,"amount":56010.08,"timestamp":1751562243388},"delay":0,"floatShares":14942670,"shares":36497677,"eps":-2.744216,"marketStatus":"Market Closed","change":0.24,"latestTime":"07-03 13:00:00 EDT","open":12.06,"high":12.57,"low":11.9517,"amount":742277.3581,"amplitude":0.052398,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.744216,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751875200000},"marketStatusCode":7,"adr":0,"listingDate":1717732800000,"exchange":"NASDAQ","adjPreClose":11.8,"postHourTrading":{"tag":"盘后","latestPrice":12.04,"preClose":12.04,"latestTime":"13:04 EDT","volume":4652,"amount":56010.08,"timestamp":1751562243388},"volumeRatio":0.5438172310130271,"impliedVol":0.1621,"impliedVolPercentile":0.0724},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAPP\",,,,,undefined,":{"symbol":"RAPP","floatShares":14942670,"roa":"-22.89%","roe":"-33.14%","lyrEps":-3.775953,"volumeRatio":0.5438172310130271,"shares":36497677,"dividePrice":0,"high":12.57,"amplitude":0.052398,"preClose":11.8,"low":11.9517,"week52Low":6.43,"pbRate":"1.54","week52High":29.74,"institutionHeld":0,"latestPrice":12.04,"eps":-2.744216,"divideRate":0,"volume":60881,"delay":0,"ttmEps":-2.744216,"open":12.06,"prevYearClose":17.74,"prevWeekClose":11.43,"prevMonthClose":11.37,"prevQuarterClose":11.37,"fiveDayClose":11.81,"twentyDayClose":13.06,"sixtyDayClose":9.51},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAPP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2548031410","title":"Rapport Therapeutics files to sell 470,589 shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2548031410","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548031410?lang=en_us&edition=fundamental","pubTime":"2025-07-01 19:00","pubTimestamp":1751367614,"startTime":"0","endTime":"0","summary":"06:59 EDT Rapport Therapeutics (RAPP) files to sell 470,589 shares of common stock for holders Published first on TheFly – the ultimate source for ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-files-to-sell-470589-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-files-to-sell-470589-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","RAPP","BK4139","BK4007","LENZ"],"gpt_icon":0},{"id":"2548008097","title":"Rapport Therapeutics Files Prospectus Relates to Proposed Resale From Time to Time by Selling Stockholder of up to 470,589 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2548008097","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548008097?lang=en_us&edition=fundamental","pubTime":"2025-07-01 18:57","pubTimestamp":1751367437,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nFWN3SY053:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"2548500879","title":"Rapport Therapeutics Inc: Sales Agreement Prospectus Covers Offer of Shares of Common Stock of up to $150 Mln From Time to Time","url":"https://stock-news.laohu8.com/highlight/detail?id=2548500879","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548500879?lang=en_us&edition=fundamental","pubTime":"2025-07-01 18:52","pubTimestamp":1751367160,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nFWN3SY07L:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"2548008761","title":"Rapport Therapeutics Inc Files for Mixed Shelf of up to $400 Mln – SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2548008761","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548008761?lang=en_us&edition=fundamental","pubTime":"2025-07-01 18:52","pubTimestamp":1751367160,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nFWN3SY07L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"2544188603","title":"Rapport Therapeutics Inc. Held Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2544188603","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544188603?lang=en_us&edition=fundamental","pubTime":"2025-06-19 04:31","pubTimestamp":1750278663,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 18, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250618:nNDL4QShRR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2544518883","title":"Chief Scientific Officer David Bredt Reports Disposal of Common Shares of Rapport Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2544518883","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544518883?lang=en_us&edition=fundamental","pubTime":"2025-06-19 04:15","pubTimestamp":1750277744,"startTime":"0","endTime":"0","summary":"David Bredt, the Chief Scientific Officer of Rapport Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 18, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250618:nNDL4BkWzR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Chief Scientific Officer David Bredt Reports Disposal of Common Shares of Rapport Therapeutics Inc","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"2540087637","title":"Analysts Offer Insights on NA Companies: Tempus AI, Inc. Class A (TEM) and Rapport Therapeutics, Inc. (RAPP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2540087637","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540087637?lang=en_us&edition=fundamental","pubTime":"2025-06-03 23:10","pubTimestamp":1748963410,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on Tempus AI, Inc. Class A (TEM – Research Report) and Rapport ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-tempus-ai-inc-class-a-tem-and-rapport-therapeutics-inc-rapp-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-tempus-ai-inc-class-a-tem-and-rapport-therapeutics-inc-rapp-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","LU1861559042.SGD","BK4611","NA","BK4613","BK4007","TEM","LU1861558580.USD","RAPP","BK4141"],"gpt_icon":0},{"id":"2540377569","title":"Stifel Nicolaus Keeps Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2540377569","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540377569?lang=en_us&edition=fundamental","pubTime":"2025-06-03 18:47","pubTimestamp":1748947679,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Paul Matteis reiterated a Buy rating on Rapport Therapeutics, Inc. (RAPP – Research Report) yesterday. The company’s shares...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-rapport-therapeutics-inc-rapp-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-rapport-therapeutics-inc-rapp-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","RAPP"],"gpt_icon":0},{"id":"2540130847","title":"Rapport Therapeutics Completes Enrollment for Phase 2a Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2540130847","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540130847?lang=en_us&edition=fundamental","pubTime":"2025-06-03 04:34","pubTimestamp":1748896471,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics, Inc. ( ($RAPP) ) has shared an announcement. On June 2, 2025, Rapport Therapeutics announced that its Phase 2a trial for RAP-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-completes-enrollment-for-phase-2a-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-completes-enrollment-for-phase-2a-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","LENZ","RAPP","BK4007"],"gpt_icon":0},{"id":"2540790248","title":"Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2540790248","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540790248?lang=en_us&edition=fundamental","pubTime":"2025-06-03 02:45","pubTimestamp":1748889900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nTUA3GYKNB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"2538286468","title":"Rapport Therapeutics Inc. Set to Participate in Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2538286468","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538286468?lang=en_us&edition=fundamental","pubTime":"2025-05-27 19:00","pubTimestamp":1748343618,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics Inc., a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders, will participate in the Jefferies Global Healthcare Conference in New York City. The company's management is scheduled for a fireside chat on Wednesday, June 4, 2025, at 10:30 a.m. Eastern Time.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on May 27, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nNDL1cJ91Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2095319765.USD","BK4112","LU2210150020.SGD","BK4588","LU2210149790.SGD","BK4007","BK4585","IE00BKPKM429.USD","RAPP","IE00BGHQF748.EUR","NDAQ","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2537823709","title":"Rapport Therapeutics Inc. to Host Inaugural Investor and Analyst Day in New York City","url":"https://stock-news.laohu8.com/highlight/detail?id=2537823709","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537823709?lang=en_us&edition=fundamental","pubTime":"2025-05-21 19:00","pubTimestamp":1747825234,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics Inc., a clinical-stage biotechnology company, will host its inaugural Investor and Analyst Day on June 2, 2025, in New York City. The event will focus on the company's clinical programs, highlighting the RAP-219 Phase 2a trial in refractory focal epilepsy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on May 21, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nNDL6yXrnh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00B64PRP62.GBP","LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","LU2210149790.SGD","LU2095319765.USD","IE00BKPKM429.USD","RAPP","BK4007","IE00B3QW5Z07.USD","NDAQ","BK4588"],"gpt_icon":0},{"id":"2536763081","title":"Chief Scientific Officer David Bredt Reports Disposal of Common Shares of Rapport Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2536763081","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536763081?lang=en_us&edition=fundamental","pubTime":"2025-05-20 04:31","pubTimestamp":1747686674,"startTime":"0","endTime":"0","summary":"David Bredt, the Chief Scientific Officer of Rapport Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 19, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250519:nNDL4gyPmd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2534413079","title":"Rapport Therapeutics Reports Q1 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2534413079","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534413079?lang=en_us&edition=fundamental","pubTime":"2025-05-10 12:20","pubTimestamp":1746850828,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics, Inc. ( ($RAPP) ) has released its Q1 earnings. Here is a breakdown of the information Rapport Therapeutics, Inc. presented to...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-reports-q1-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-reports-q1-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RAPP","BK4539","LENZ","BK4007"],"gpt_icon":0},{"id":"2534034157","title":"Optimistic Buy Rating for Rapport Therapeutics Driven by Promising RAP-219 Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2534034157","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534034157?lang=en_us&edition=fundamental","pubTime":"2025-05-09 02:05","pubTimestamp":1746727556,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Joseph Thome has maintained their bullish stance on RAPP stock, giving a Buy rating today. Joseph Thome has given his Buy rating d...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-rapport-therapeutics-driven-by-promising-rap-219-developments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-rapport-therapeutics-driven-by-promising-rap-219-developments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP","LENZ"],"gpt_icon":0},{"id":"2533326091","title":"Promising Clinical Developments and Strategic Initiatives Drive Buy Rating for Rapport Therapeutics, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2533326091","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533326091?lang=en_us&edition=fundamental","pubTime":"2025-05-08 22:35","pubTimestamp":1746714923,"startTime":"0","endTime":"0","summary":"Analyst Justin Walsh of JonesTrading reiterated a Buy rating on Rapport Therapeutics, Inc. (RAPP – Research Report), retaining the price target of ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-clinical-developments-and-strategic-initiatives-drive-buy-rating-for-rapport-therapeutics-inc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-clinical-developments-and-strategic-initiatives-drive-buy-rating-for-rapport-therapeutics-inc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP"],"gpt_icon":0},{"id":"2533185819","title":"Rapport Therapeutics Inc - Rap-219 Phase 2a Trial Results Expected Q3 2025 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2533185819","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533185819?lang=en_us&edition=fundamental","pubTime":"2025-05-08 19:17","pubTimestamp":1746703077,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nFWN3RG1IU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2533183021","title":"Rapport Therapeutics Q1 EPS $(0.68) Beats $(0.76) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2533183021","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533183021?lang=en_us&edition=fundamental","pubTime":"2025-05-08 19:15","pubTimestamp":1746702907,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.68) per share which beat the analyst consensus estimate of $(0.76) by 10.53 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45281379/rapport-therapeutics-q1-eps-0-68-beats-0-76-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","LENZ"],"gpt_icon":0},{"id":"2533093134","title":"-Charles River agrees with Elliott to add new directors, review business","url":"https://stock-news.laohu8.com/highlight/detail?id=2533093134","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533093134?lang=en_us&edition=fundamental","pubTime":"2025-05-07 22:10","pubTimestamp":1746627051,"startTime":"0","endTime":"0","summary":"UPDATE 1--Charles River agrees with Elliott to add new directors, review businessAdds details on other board members in paragraph 3By Svea Herbst-Bayliss","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nL1N3RF0TB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1551013342.USD","RAPP","LU0882574055.USD","LU0310800379.SGD","LU0612318971.USD","LU1267930490.SGD","IE00B19Z3B42.SGD","LU0234572021.USD","LU1244550494.USD","IE00BWDBJ516.SGD","LU1815336091.USD","LU0912757837.SGD","LU1880398471.USD","LU2133065610.SGD","RIO.UK","LU0965509283.SGD","IE0034235071.USD","LU1929549753.HKD","LU0320765646.SGD","LU0203345920.USD","IE00B2B36J28.USD","LU2089984988.USD","LU1732799900.SGD","LU2087621335.USD","LU0792757196.USD","LU1057294990.SGD","SG9999015978.USD","BK4550","LU1130305938.SGD","BK4581","LU0630314457.HKD","LU1430597077.USD","LU2468319806.SGD","LU0234570918.USD","BK4559","IE00BJT1NW94.SGD","IE00B3PB1722.GBP","IE00BSNM7G36.USD","ABBV","IE0002141913.USD","LU0738911758.USD","SG9999001440.SGD","LU0661504455.SGD","CAH","LU1989771016.USD","LU0052756011.USD","LU0114720955.EUR","CRL","LU0889566641.SGD","LU0128525689.USD"],"gpt_icon":0},{"id":"2531033733","title":"Stifel Nicolaus Sticks to Its Buy Rating for Rapport Therapeutics, Inc. (RAPP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2531033733","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531033733?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:19","pubTimestamp":1746011968,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Paul Matteis reiterated a Buy rating on Rapport Therapeutics, Inc. (RAPP – Research Report) today and set a price target of...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-its-buy-rating-for-rapport-therapeutics-inc-rapp?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-its-buy-rating-for-rapport-therapeutics-inc-rapp?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP","SF"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":41,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAPP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-08","symbol":"RAPP","fiscalQuarterEnding":"2025/03","expectedEps":-0.77,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2025-03-11","symbol":"RAPP","fiscalQuarterEnding":"2024/12","expectedEps":-0.62,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741665600000,"reportTimeType":"pre","actualEps":-0.57},{"market":"US","date":"2024-11-07","symbol":"RAPP","fiscalQuarterEnding":"2024/09","expectedEps":-0.57,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"pre","actualEps":-0.5}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAPP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RAPP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1744171200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RAPP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RAPP","date":"2025-07-03","current":-5.513507,"percent":0.70632,"low":-19.654107,"twenty":-14.247974,"median":-9.698265,"eighty":-5.011596,"high":-3.640031,"avg":-9.726924,"sd":4.328744,"marketCap":439432031},"quantilePoints":[{"date":"2024-06-07","current":-14.341434,"twenty":-13.293406,"median":-11.721364,"eighty":-11.721364,"marketCap":735830305},{"date":"2024-06-14","current":-17.322989,"twenty":-16.966549,"median":-15.024031,"eighty":-12.769392,"marketCap":888807905},{"date":"2024-06-21","current":-15.733266,"twenty":-17.881887,"median":-15.772475,"eighty":-14.348329,"marketCap":807242405},{"date":"2024-06-28","current":-16.581593,"twenty":-17.17471,"median":-16.18238,"eighty":-14.635158,"marketCap":850768389},{"date":"2024-07-05","current":-17.059223,"twenty":-17.829134,"median":-16.431888,"eighty":-15.672154,"marketCap":875274616},{"date":"2024-07-12","current":-18.299635,"twenty":-18.057796,"median":-16.595851,"eighty":-15.733266,"marketCap":938917651},{"date":"2024-07-19","current":-14.343149,"twenty":-18.092899,"median":-16.610109,"eighty":-15.733266,"marketCap":735918314},{"date":"2024-07-26","current":-16.431888,"twenty":-18.057796,"median":-16.50674,"eighty":-14.592658,"marketCap":843087333},{"date":"2024-08-02","current":-15.740395,"twenty":-18.021611,"median":-16.417631,"eighty":-14.614044,"marketCap":807608170},{"date":"2024-08-09","current":-11.062669,"twenty":-17.829134,"median":-16.189509,"eighty":-14.507112,"marketCap":697147270},{"date":"2024-08-16","current":-12.078391,"twenty":-17.822005,"median":-15.897228,"eighty":-14.341434,"marketCap":761156070},{"date":"2024-08-23","current":-12.943207,"twenty":-17.322989,"median":-15.776039,"eighty":-12.769083,"marketCap":815654991},{"date":"2024-08-30","current":-12.623979,"twenty":-17.301602,"median":-15.672154,"eighty":-12.252515,"marketCap":795537939},{"date":"2024-09-06","current":-11.799793,"twenty":-17.107699,"median":-14.956226,"eighty":-12.030797,"marketCap":743599370},{"date":"2024-09-13","current":-11.027844,"twenty":-17.007896,"median":-14.603351,"eighty":-11.813723,"marketCap":694952683},{"date":"2024-09-20","current":-12.322165,"twenty":-16.6871,"median":-14.421566,"eighty":-11.752199,"marketCap":776518182},{"date":"2024-09-27","current":-12.380206,"twenty":-16.587296,"median":-14.342291,"eighty":-11.752199,"marketCap":780175827},{"date":"2024-10-04","current":-12.072587,"twenty":-16.581593,"median":-13.041877,"eighty":-11.742318,"marketCap":760790305},{"date":"2024-10-11","current":-12.798103,"twenty":-16.461829,"median":-12.783593,"eighty":-11.721364,"marketCap":806510876},{"date":"2024-10-18","current":-15.061713,"twenty":-16.461829,"median":-13.041877,"eighty":-11.742318,"marketCap":949159059},{"date":"2024-10-25","current":-14.057599,"twenty":-16.431888,"median":-14.106934,"eighty":-11.752199,"marketCap":885881788},{"date":"2024-11-01","current":-14.289764,"twenty":-16.420482,"median":-14.289764,"eighty":-11.78122,"marketCap":900512371},{"date":"2024-11-08","current":-13.587752,"twenty":-16.360601,"median":-14.196898,"eighty":-11.792828,"marketCap":976225637},{"date":"2024-11-15","current":-10.665545,"twenty":-16.293733,"median":-13.709352,"eighty":-11.752199,"marketCap":766276774},{"date":"2024-11-22","current":-11.755009,"twenty":-16.213426,"median":-13.641207,"eighty":-11.719637,"marketCap":844550392},{"date":"2024-11-29","current":-11.627735,"twenty":-16.188083,"median":-13.405914,"eighty":-11.573511,"marketCap":835406277},{"date":"2024-12-06","current":-10.416089,"twenty":-16.139607,"median":-12.943207,"eighty":-11.450385,"marketCap":748354310},{"date":"2024-12-13","current":-9.555718,"twenty":-15.982774,"median":-12.73716,"eighty":-11.371152,"marketCap":686540097},{"date":"2024-12-20","current":-9.199351,"twenty":-15.858733,"median":-12.415031,"eighty":-11.254059,"marketCap":660936577},{"date":"2024-12-27","current":-9.688083,"twenty":-15.824515,"median":-12.350651,"eighty":-11.045256,"marketCap":696049976},{"date":"2025-01-03","current":-9.917175,"twenty":-15.797425,"median":-12.316361,"eighty":-10.975704,"marketCap":712509382},{"date":"2025-01-10","current":-7.539701,"twenty":-15.740395,"median":-12.304752,"eighty":-10.859002,"marketCap":541697328},{"date":"2025-01-17","current":-6.460419,"twenty":-15.733266,"median":-12.215086,"eighty":-10.644772,"marketCap":464155239},{"date":"2025-01-24","current":-7.076424,"twenty":-15.684376,"median":-12.087097,"eighty":-10.43238,"marketCap":508412752},{"date":"2025-01-31","current":-8.354253,"twenty":-15.597056,"median":-11.915876,"eighty":-10.137105,"marketCap":600219659},{"date":"2025-02-07","current":-8.211706,"twenty":-15.257893,"median":-11.843324,"eighty":-9.686047,"marketCap":589978251},{"date":"2025-02-14","current":-8.094614,"twenty":-15.103195,"median":-11.828814,"eighty":-9.441681,"marketCap":581565666},{"date":"2025-02-21","current":-6.455328,"twenty":-15.070846,"median":-11.799793,"eighty":-9.297098,"marketCap":463789474},{"date":"2025-02-28","current":-5.106225,"twenty":-15.037336,"median":-11.771597,"eighty":-9.077168,"marketCap":366861863},{"date":"2025-03-07","current":-4.373128,"twenty":-15.01412,"median":-11.747556,"eighty":-8.771711,"marketCap":314191765},{"date":"2025-03-14","current":-4.898381,"twenty":-14.977526,"median":-11.717047,"eighty":-8.416363,"marketCap":383577552},{"date":"2025-03-21","current":-4.530187,"twenty":-14.817535,"median":-11.627735,"eighty":-8.164869,"marketCap":354745367},{"date":"2025-03-28","current":-4.68399,"twenty":-14.676319,"median":-11.461087,"eighty":-7.790176,"marketCap":366789191},{"date":"2025-04-04","current":-4.189957,"twenty":-14.640334,"median":-11.410917,"eighty":-7.133443,"marketCap":328102968},{"date":"2025-04-11","current":-4.315796,"twenty":-14.632186,"median":-11.370643,"eighty":-6.989878,"marketCap":337957006},{"date":"2025-04-17","current":-4.730597,"twenty":-14.622599,"median":-11.327444,"eighty":-6.74653,"marketCap":370438835},{"date":"2025-04-25","current":-4.949801,"twenty":-14.60549,"median":-11.189913,"eighty":-6.457364,"marketCap":387604034},{"date":"2025-05-02","current":-5.280719,"twenty":-14.55844,"median":-11.048158,"eighty":-5.528775,"marketCap":413517298},{"date":"2025-05-09","current":-4.693792,"twenty":-14.472894,"median":-10.976093,"eighty":-5.332796,"marketCap":374099938},{"date":"2025-05-16","current":-4.560992,"twenty":-14.4176,"median":-10.940782,"eighty":-5.2164,"marketCap":363515647},{"date":"2025-05-23","current":-5.092192,"twenty":-14.397354,"median":-10.8247,"eighty":-5.097805,"marketCap":405852811},{"date":"2025-05-30","current":-3.896992,"twenty":-14.370288,"median":-10.665545,"eighty":-4.981023,"marketCap":310594193},{"date":"2025-06-06","current":-5.646289,"twenty":-14.346875,"median":-10.527934,"eighty":-4.950803,"marketCap":450014853},{"date":"2025-06-13","current":-5.101351,"twenty":-14.342806,"median":-10.416089,"eighty":-4.981023,"marketCap":406582762},{"date":"2025-06-20","current":-5.050978,"twenty":-14.341434,"median":-10.309179,"eighty":-5.014344,"marketCap":402568031},{"date":"2025-06-27","current":-5.408165,"twenty":-14.289764,"median":-9.866266,"eighty":-5.000606,"marketCap":431036124},{"date":"2025-07-03","current":-5.513507,"twenty":-14.247974,"median":-9.698265,"eighty":-5.011596,"marketCap":439432031}],"updateTime":1751779544466}}}